GlassScriptPhysician profile
Jennifer L Bailey
NPI 1043244403
$4,852.09
in general payments reported to CMS, 2019-2025
21 companies · $2,337 in 2025
The $2,337 reported for 2025 was more than what 95% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $105 · 2021: $368 · 2022: $179 · 2023: $101 · 2024: $1,661 · 2025: $2,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,600 · Food and Beverage: $499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,600.00 |
| Food and Beverage | $499.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $3,600.00 | 2024-2025 | Bovine Collagen |
| Abbvie INC. | $260.57 | 2019-2023 | Liletta |
| Astellas Pharma US INC | $227.32 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $170.22 | 2019-2024 | Slynd |
| Novartis Pharmaceuticals Corporation | $146.23 | 2019-2022 | |
| Pfizer INC. | $90.01 | 2019-2023 | |
| Inari Medical, INC. | $86.78 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Hologic Sales and Service, LLC | $53.13 | 2024-2025 | Thinprep 2000 Processor, Novasure |
| Therapeuticsmd, INC. | $30.02 | 2019-2021 | |
| Dexcom, INC. | $24.63 | 2025 | Dexcom G6 Transmitter |
| Evofem Biosciences, INC. | $24.33 | 2022 | |
| Coopersurgical, INC. | $20.43 | 2021 | |
| Sumitomo Pharma America, INC. | $18.88 | 2025 | Myfembree |
| Biohaven Pharmaceuticals, INC. | $17.01 | 2021 | |
| Meditrina | $16.93 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $15.97 | 2021 | |
| Dysis Medical, INC. | $14.11 | 2021 | |
| Allergan, INC. | $12.62 | 2019 | |
| Organon LLC | $11.57 | 2021 | |
| Merck Sharp & Dohme LLC | $11.33 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.